General Information:

Id: 1,572
Diseases: Atherosclerosis
Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
article
Reference: Mandosi E et al.(2010) Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes J. Atheroscler. Thromb. 17: 539-545 [PMID: 20134099]

Interaction Information:

Comment Type 2 diabetic patients were treated for 8 weeks with atorvastatin, atorvastatin decreased total cholesterol and LDL cholesterol, and increased HDL cholesterol.
Formal Description
Interaction-ID: 11256

drug/chemical compound

Atorvastatin

decreases_quantity of

drug/chemical compound

Cholesterol

in blood
Drugbank entries Show/Hide entries for Atorvastatin or Cholesterol
Comment Type 2 diabetic patients were treated for 8 weeks with atorvastatin, atorvastatin decreased total cholesterol and LDL cholesterol, and increased HDL cholesterol.
Formal Description
Interaction-ID: 11257

drug/chemical compound

Atorvastatin

decreases_quantity of

complex/PPI

LDL

in blood
Drugbank entries Show/Hide entries for Atorvastatin
Comment Type 2 diabetic patients were treated for 8 weeks with atorvastatin, atorvastatin decreased total cholesterol and LDL cholesterol, and increased HDL cholesterol.
Formal Description
Interaction-ID: 11258

drug/chemical compound

Atorvastatin

increases_quantity of

complex/PPI

HDL

in blood
Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin reduced nuclear and increased cytoplasm NFkappaB levels.
Formal Description
Interaction-ID: 11259

drug/chemical compound

Atorvastatin

decreases_quantity of

complex/PPI

NF-kappaB complex

in nucleus
Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin reduced nuclear and increased cytoplasm NFkappaB levels.
Formal Description
Interaction-ID: 11260

drug/chemical compound

Atorvastatin

increases_quantity of

complex/PPI

NF-kappaB complex

in cytoplasm
Drugbank entries Show/Hide entries for Atorvastatin
Comment TNFalpha production in lipopolysaccharide-activated monocytes from patients treated with atorvastatin was reduced.
Formal Description
Interaction-ID: 11264

drug/chemical compound

Atorvastatin

decreases_quantity of

gene/protein

TNF

in lipopolysaccharide-activated monocytes
Drugbank entries Show/Hide entries for Atorvastatin or TNF
Comment Atorvastatin therapy, beside lowering serum cholesterol levels, could exert anti-atherogenic and anti-inflammatory effects in type 2 diabetic patients.
Formal Description
Interaction-ID: 11265

drug/chemical compound

Atorvastatin

decreases_activity of

in type 2 diabetics
Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin therapy, beside lowering serum cholesterol levels, could exert anti-atherogenic and anti-inflammatory effects in type 2 diabetic patients.
Formal Description
Interaction-ID: 13618

drug/chemical compound

Atorvastatin

decreases_activity of

in type 2 diabetics
Drugbank entries Show/Hide entries for Atorvastatin